ASCLETIS ANNOUNCES FIRST PARTICIPANT DOSED IN A GLOBAL PHASE III CLINICAL PROGRAM OF ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST ASC30 FOR CHRONIC WEIGHT MANAGEMENT

Reuters · 1d ago

Please log in to view news